FDA approves Braftovi with Erbitux for metastatic colorectal cancer subset

The FDA approved encorafenib in combination with cetuximab for adults with previously treated BRAF V600E-mutant metastatic colorectal cancer.Encorafenib (Braftovi, Pfizer) is an oral small molecule kinase inhibitor that targets BRAF V600E. Cetuximab (Erbitux, Eli Lilly) is an epidermal growth factor receptor inhibitor.The FDA based the approval on results of the randomized phase 3 BEACON CRC trial, which included patients with BRAF V600E-mutant metastatic colorectal cancer that progressed after one or two prior regimens.Researchers randomly assigned patients 1:1:1 to one of three treatments:Read More

Share on facebook
Share on twitter
Share on linkedin